Brokerages Set AstraZeneca PLC (LON:AZN) Target Price at £143.33

Shares of AstraZeneca PLC (LON:AZN) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is £145.83.

A number of analysts recently commented on the company. Berenberg Bank increased their price objective on AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research note on Tuesday. Jefferies Financial Group restated a “buy” rating and issued a £150 target price on shares of AstraZeneca in a report on Monday, November 10th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a research report on Thursday, January 15th.

AstraZeneca Price Performance

AZN stock opened at £134.60 on Tuesday. The stock’s 50 day moving average price is £137.62 and its 200 day moving average price is £125.66. The firm has a market cap of £208.67 billion, a P/E ratio of 22.36, a PEG ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. AstraZeneca has a 1 year low of GBX 9,573.51 and a 1 year high of £144.10.

Insider Activity

In other news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. 0.14% of the stock is owned by company insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.